

3D Simulation Predictive Modeling in Large Annulus Bicuspid Aortic Stenosis With Cardiogenic Shock

Joseph Aragon MD¹, Michael Shenoda MD¹, Colin Shafer MD¹, Samantha Yim RN¹,
Matthew Abrams² Michael Paulsen MD¹, Dominic Tedesco MD¹, Peter Baay MD¹



TRANSCATHETER
CARDIOVASCULAR
THERAPEUTICS®

1. Santa Barbara Cottage , Santa Barbara, CA, USA
2. DASI Simulations, Dublin, Ohio , USA

Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Royalties/Patent Beneficiary

Executive Role/Ownership Interest

Other Financial Benefit

Ineligible Company

Boston Scientific


WL Gore, Edwards Lifesciences,
Boston Scientific

Case Presentation

- A 67 year old male was referred for evaluation of aortic stenosis and low EF. He had a history of alcoholic cardiomyopathy and CHF with Class 3 symptoms.
- Echo demonstrated a bicuspid valve peak gradient 32 mm Hg mean gradient 18 mm Hg, LVEF of 10%-20%.
- He acutely decompensated within 1 week of initial evaluation and was admitted in cardiogenic shock.

Aortic annular area of 924 mm²



LVOT 1102 mm²





SOV Avg 44mm


**Heart Team discussion-
Not a surgical candidate**



**LCA 24mm and RCA 26mm
STJ 41mm**

Case Details

Age	67
Sex	Male
Valve Type	Bicuspid
Annulus Area & Phase [1]	941.0 mm ² (Diastolic)
Segmentation Phase	Diastolic
CT Quality	Motion artifact, No full multiphase
Additional Notes	Prospective, In TAVR queue / inpatient, please model Sapien 29 mm nominal to 9 cc overexpansion;



[1. Blanke P et. al., J Am Coll Cardiol Img. 2019 Jan; 12 \(1\) 1-24](#)

These simulations are provided for research purposes and/or regulated under the 21st Century Cures Act, a U.S. federal law designed to accelerate medical product development and innovation. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Users should acknowledge that these simulations operate under the assumption of certain parameters and may not fully account for all potential variations in individual patient anatomy including material and tissue properties, and procedural factors including pre and post dilation. Deviations from these assumptions or variations in individual patient conditions could affect the accuracy of the simulation results. Users are encouraged to review the accompanying documentation and consult with healthcare professionals as needed to ensure proper understanding and compliance with applicable regulations. Physicians and other health care practitioners should exercise independent professional judgment in consideration of the inherent assumptions and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history, symptoms, and other preprocedural evaluations for TAVR.

Case Summary

Valve	% Oversizing [2]	Coronary Analysis [3,4]	Stent Apposition	Stretch Analysis [5]
BE 29	-31.0% undersized	LCA DLC/d = 3.8 RCA DLC/d = 3.4	Largest gap = 2.9 mm	Max Stretch 1.0
BE 29 +5cc	N/A	LCA DLC/d = 3.7 RCA DLC/d = 3.2	Largest gap = 1.5 mm	Max Stretch 1.2
BE 29 +9cc	N/A	LCA DLC/d = 3.7 RCA DLC/d = 3.1	Largest gap = 0.2 mm	Max Stretch 1.2

DLC=distance of leaflet to coronary

d=diameter of coronary

<0.7=high risk of obstruction

0.7-1 intermediate risk

>1 low risk

Gap Analysis <2.5 mm 0 – trace PVL

Stretch Analysis >1.5 increased risk for annular injury

[2. Blanke P, et. al., JACC: Cardiovascular Interventions \(2017\)](#)

[3. Holst K, et. al., The Annals of Thoracic Surgery \(2024\)](#)


[4. Heitkemper M, et. al., J Thorac Cardiovasc Surg. \(2020\)](#)

[5. Sirset, T. et al. J Am Coll Cardiol Intv. \(2023\)](#)

These simulations are provided for research purposes and/or regulated under the 21st Century Cures Act, a U.S. federal law designed to accelerate medical product development and innovation. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Users should acknowledge that these simulations operate under the assumption of certain parameters and may not fully account for all potential variations in individual patient anatomy including material and tissue properties, and procedural factors including pre and post dilation. Deviations from these assumptions or variations in individual patient conditions could affect the accuracy of the simulation results. Users are encouraged to review the accompanying documentation and consult with healthcare professionals as needed to ensure proper understanding and compliance with applicable regulations. Physicians and other health care practitioners should exercise independent professional judgment in consideration of the inherent assumptions and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history, and other relevant information.

Balloon-Expandable 29 +5cc Expansion Animation


- Left-Coronary Cusp
- Right-Coronary Cusp




These simulations are provided for research purposes and/or regulated under the 21st Century Cures Act, a U.S. federal law designed to accelerate medical product development and innovation. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Users should acknowledge that these simulations operate under the assumption of certain parameters and may not fully account for all potential variations in individual patient anatomy including material and tissue properties, and procedural factors including pre and post dilation. Deviations from these assumptions or variations in individual patient conditions could affect the accuracy of the simulation results. Users are encouraged to review the accompanying documentation and consult with healthcare professionals as needed to ensure proper understanding and compliance with applicable regulations. Physicians and other health care practitioners should exercise independent professional judgment in consideration of the inherent assumptions and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history,

Balloon-Expandable 29 +5cc THV Apposition

Flow Trajectories



Annulus View




- **Left-Coronary Cusp**
- **Right-Coronary Cusp**


Gap Assessment

Gap	Thickness [mm]
I	1.5
II	0.8

These simulations are provided for research purposes and/or regulated under the 21st Century Cures Act, a U.S. federal law designed to accelerate medical product development and innovation. This product is not approved to diagnose, treat, cure, or prevent any disease. DASI Simulations provides simulations for several THV deployment options. Simulations can cover a mix of appropriate and suboptimal options. Appropriate alternatives may exist. Content is not intended to establish or recommend a standard of care to be followed. Users should acknowledge that these simulations operate under the assumption of certain parameters and may not fully account for all potential variations in individual patient anatomy including material and tissue properties, and procedural factors including pre and post dilation. Deviations from these assumptions or variations in individual patient conditions could affect the accuracy of the simulation results. Users are encouraged to review the accompanying documentation and consult with healthcare professionals as needed to ensure proper understanding and compliance with applicable regulations. Physicians and other health care practitioners should exercise independent professional judgment in consideration of the inherent assumptions and use the simulation results in conjunction with the THV's Instruction-for-Use, the patient's clinical history,




Right transfemoral with GA and TEE guidance



29 mm Sapien 3 Ultra Resilia +5 cc

Follow Up

- Discharged in 24hr
- Follow up echo at 1 month showed modest improvement in LVEF, no PVL or central AI
- Class I symptoms



Conclusion

- The use of predictive modeling software was essential to success of the case.
- +5cc for balloon volume predicted the lowest risk of **rupture**, significant PVL, central AI and embolization.
- Our Heart Team has elected to perform DASI modeling on cases with large annuli, borderline coronary heights, and all patients younger than 75 years old.

Thank You

